FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma

On August 9, 2023, the Food and Drug Administration granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech, Inc.)

Source: FDA Center for Drug Evaluation and Research - What's New - August 10, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news